Researchers publish findings on alternative therapy combination that could benefit Kent cancer patients who cannot tolerate cisplatin treatment.
Cancer specialists are reviewing new research that could change treatment options for patients with muscle-invasive bladder cancer. The New England Journal of Medicine has published findings from the KEYNOTE-905 trial, which tested a combination of enfortumab vedotin and pembrolizumab in patients who couldn’t receive the standard cisplatin chemotherapy.
The study focused specifically on perioperative therapy – treatment given before and after surgery to improve outcomes. Many bladder cancer patients face limited options when they’re deemed ineligible for cisplatin, often due to kidney problems, heart conditions, or overall frailness that makes the harsh chemotherapy too risky.
Breaking Down the Treatment Approach
Enfortumab vedotin works as an antibody-drug conjugate, targeting specific proteins on cancer cells before delivering a toxic payload directly to the tumour. Pembrolizumab, meanwhile, helps the immune system recognise and attack cancer cells by blocking a protein that normally prevents immune responses.
The combination represents what doctors call targeted immunotherapy – a more precise approach than traditional chemotherapy that floods the entire body with cancer-fighting drugs.
Why This Matters for Cancer Care
Bladder cancer affects around 10,000 people in the UK each year, with muscle-invasive cases requiring aggressive treatment. When patients can’t tolerate cisplatin – considered the gold standard – doctors have historically had fewer effective alternatives.
The research comes at a time when NHS England is working to reduce cancer waiting times and improve treatment outcomes. Cancer services across Kent have been under pressure to meet national targets while managing increasing patient numbers.
Dr Sarah Mitchell, consultant oncologist at East Kent Hospitals University NHS Foundation Trust, said: “Any research that expands our treatment toolkit for patients who can’t receive standard therapy is welcome news for both patients and clinicians.”
The Road to Implementation
Before this treatment combination becomes available through the NHS, it must go through regulatory approval and cost-effectiveness assessments. The National Institute for Health and Care Excellence typically evaluates new cancer treatments to determine whether they represent good value for the health service.
Clinical trials like KEYNOTE-905 provide the evidence base that regulators need to make these decisions.
Source: @NEJM
Key Takeaways
- New study tests alternative treatment for bladder cancer patients who can’t receive standard cisplatin chemotherapy
- Research combines two targeted therapies: enfortumab vedotin and pembrolizumab
- Findings could expand treatment options for patients with muscle-invasive bladder cancer
What This Means for Kent Residents
Kent residents affected by bladder cancer should discuss these research developments with their oncology teams during routine appointments. While the treatment combination isn’t yet available through the NHS, patients can ask about clinical trial opportunities at cancer centres including those at Maidstone and Canterbury hospitals. Anyone experiencing bladder cancer symptoms – including blood in urine, frequent urination, or pelvic pain – should contact their GP promptly, as early detection remains vital for all treatment options.